Safety, Tolerability, and Pharmacokinetics of SMT C1100, a 2-Arylbenzoxazole Utrophin Modulator, following Single- and Multiple-Dose Administration to Pediatric Patients with Duchenne Muscular DystrophyValeria Ricotti, Jonathon M. Tinsley, Stefan Spinty et al.|PLoS ONE|2016Cited by 53
A Phase 1b Trial to Assess the Pharmacokinetics of Ezutromid in Pediatric Duchenne Muscular Dystrophy Patients on a Balanced DietFrancesco Muntoni, Jonathon M. Tinsley, Stefan Spinty et al.|Clinical Pharmacology in Drug Development|2019Cited by 40
PhaseOut DMD: a Phase 2, proof of concept, clinical study of utrophin modulation with ezutromidF. Muntoni, Jonathon M. Tinsley, Kate Maresh et al.|Neuromuscular Disorders|2017Cited by 9
Utrophin modulators to treat Duchenne muscular dystrophy (DMD): Phase 1b Clinical Trial Results of SMT C1100 (P2.006)Jon Tinsley, Kay E. Davies, Francesco Muntoni et al.|Neurology|2015Cited by 1
Utrophin modulators to treat Duchenne muscular dystrophy (DMD): Results from a Phase 1b Clinical Trial of SMT C1100Jonathon M. Tinsley, Kelvin J.A. Davies, F. Muntoni et al.|Neuromuscular Disorders|2015Cited by 0